ストックスクリーナーアプリを入手
26.62
1.10%
0.29
前日終値:
$26.33
開ける：
$26.12
24時間の取引高:
589.66K
Relative Volume:
0.54
時価総額：
$2.01B
収益：
$122.87M
当期純損益:
$-73.68M
株価収益率:
-27.15
EPS:
-0.9803
ネットキャッシュフロー:
$-39.27M
1週間 パフォーマンス:
-0.93%
1か月 パフォーマンス:
+6.06%
6か月 パフォーマンス:
+106.52%
1年 パフォーマンス:
+80.11%
1日の値動き範囲:
$25.68
$26.84
1週間の範囲:
$25.68
$26.91
52週間の値動き範囲:
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
名前
Zymeworks Inc.
セクター
電話
604-678-1388
住所
1385 West 8th Avenue, Suite 540, Vancouver, BC
ZYME を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
26.62 | 1.99B | 122.87M | -73.68M | -39.27M | -0.9803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-12 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-10-24 | 再開されました | Wells Fargo | Equal Weight |
| 2025-10-14 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | 開始されました | B. Riley Securities | Buy |
| 2025-05-20 | 開始されました | TD Cowen | Buy |
| 2024-12-16 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-07 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 再開されました | Wells Fargo | Overweight |
| 2023-01-04 | 繰り返されました | H.C. Wainwright | Neutral |
| 2022-12-20 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 再開されました | Wells Fargo | Overweight |
| 2022-05-05 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-03-15 | 開始されました | Evercore ISI | Outperform |
| 2021-12-10 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 再開されました | Guggenheim | Neutral |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-02-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 再開されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-08-06 | 開始されました | SVB Leerink | Outperform |
| 2020-01-10 | 開始されました | Wolfe Research | Outperform |
| 2019-12-09 | 開始されました | JP Morgan | Neutral |
| 2019-11-25 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
| 2019-09-30 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 開始されました | Stifel | Buy |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2018-05-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 開始されました | Raymond James | Outperform |
すべてを表示
Zymeworks Inc. (ZYME) 最新ニュース
Zymeworks Inc: Can ZYME’s Quiet Rally Turn Into a Breakout Story? - AD HOC NEWS
Zymeworks shareholders elect directors and approve compensation at annual meeting - Investing.com
Zymeworks Shareholders Back Directors, Executive Pay and Auditor - TipRanks
Short Interest in Zymeworks Inc. (NASDAQ:ZYME) Drops By 29.8% - MarketBeat
Zymeworks Announces Participation in Upcoming Investor Conferences - Macau Business
Kenneth Galbraith Sells 47,528 Shares of Zymeworks (NYSE:ZYME) Stock - MarketBeat
Zymeworks Insider Sold Shares Worth $1,284,311, According to a Recent SEC Filing - marketscreener.com
Is Zymeworks Inc. stock vulnerable to regulatory risksBull Run & Daily Chart Pattern Signal Reports - Улправда
How rising interest rates impact Zymeworks Inc. stockIndex Update & AI Based Buy/Sell Signal Reports - ulpravda.ru
Zymeworks Inc. $ZYME Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Aug Fed Impact: How rising interest rates impact Zymeworks Inc. stockTrade Entry Report & Expert-Curated Trade Recommendations - Улправда
Will Zymeworks Inc. stock benefit from upcoming earnings reportsProduct Launch & Technical Confirmation Alerts - Улправда
Why retail investors pile into Zymeworks Inc. stock2025 Winners & Losers & Low Drawdown Investment Strategies - DonanımHaber
Is Zymeworks Inc. (NASDAQ:ZYME) Trading At A 50% Discount? - Yahoo Finance
Zymeworks Inc. $ZYME Shares Acquired by Squarepoint Ops LLC - MarketBeat
Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Buy" from Analysts - MarketBeat
How institutional buying supports Zymeworks Inc. stockPortfolio Gains Report & Community Verified Swing Trade Signals - ulpravda.ru
Free cash flow per share of Zymeworks Inc. – TRADEGATE:ZA8 - TradingView — Track All Markets
Buy Signal: How rising interest rates impact Zymeworks Inc. stockMarket Activity Recap & Trade Opportunity Analysis - Улправда
Will Zymeworks Inc. (ZA8) stock return to pre crash levelsJuly 2025 PreEarnings & Smart Money Movement Alerts - Улправда
Truist Initiates Zymeworks at Buy With $40 Price Target - marketscreener.com
How FDA Approval of Zanidatamab in HER2 Biliary Cancer Will Impact Zymeworks (ZYME) Investors - Sahm
Zymeworks (NASDAQ:ZYME) Stock Rating Upgraded by Wells Fargo & Company - MarketBeat
Zymeworks (NYSE:ZYME) Shares Gap UpWhat's Next? - MarketBeat
Zymeworks (NASDAQ:ZYME) Shares Gap UpHere's What Happened - MarketBeat
EcoR1 Capital LLC Increases Stake in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Wells Fargo Upgrades Zymeworks (ZYME) - Nasdaq
Zymeworks (ZYME) Receives Rating Upgrade and Increased Price Tar - GuruFocus
Redmile Group LLC Sells 638,318 Shares of Zymeworks Inc. $ZYME - MarketBeat
Could Zymeworks' blockbuster drug success revive Vancouver biotech scene? - Business in Vancouver
Norges Bank Buys New Shares in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks (ZYME) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Zymeworks to Engage in Key Investor Conferences - MSN
Zymeworks (ZYME) Is Up 5.2% After First FDA Approval For Zanidatamab And Royalty ShiftHas The Bull Case Changed? - Sahm
Zymeworks (ZYME): Reassessing Valuation After FDA Zanidatamab Approval and a Sharp Share Price Rally - Sahm
Zymeworks Inc Stock Analysis and ForecastPrice Momentum Alerts & Low Entry Investment Plans - earlytimes.in
Zymeworks (ZYME) Price Target Increased by 42.94% to 35.19 - Nasdaq
How higher bond yields impact Zymeworks Inc. (ZA8) stockPortfolio Update Report & Weekly Setup with ROI Potential - Newser
Is Zymeworks Inc. (ZA8) stock cheap vs fundamentalsPortfolio Value Report & Long Hold Capital Preservation Tips - Newser
What technical patterns form on Zymeworks Inc. (ZA8) stock chartsWeekly Gains Summary & Short-Term Swing Trade Alerts - Newser
Is Zymeworks Inc. (ZA8) stock considered safe havenInsider Selling & AI Powered Market Trend Analysis - Newser
Will Zymeworks Inc. (ZA8) stock maintain strong growth2025 Earnings Impact & Safe Capital Allocation Plans - Newser
Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences - MSN
Citizens Initiates Coverage of Zymeworks (ZYME) with Market Outperform Recommendation - Nasdaq
How Zymeworks Inc. (ZA8) stock performs in volatility spikesJuly 2025 Gainers & Verified Technical Signals - Newser
Zymeworks Announces Participation in Upcoming Conferences - The Manila Times
Zymeworks Inc. Announces Participation in ASCO GI and J.P. Morgan Healthcare Conference, Highlighting Advances in HER2-Driven Gastrointestinal Cancers and Novel Drug Developments - Quiver Quantitative
Is Zymeworks Inc. (ZA8) stock supported by strong fundamentalsAnalyst Upgrade & Accurate Intraday Trade Tips - Newser
Zymeworks Inc. (ZYME) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):